Goldman Sachs
TTNP

Goldman Sachs’s Titan Pharmaceuticals TTNP Stock Holding History

Goldman Sachs’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19
Closed -$3K – 5411
2019
Q3 		$3K Buy
+19
New +$8.56K ﹤0.01% 5136
2017
Q3 		– Sell
-28
Closed -$195K – 6863
2017
Q2 		$195K Hold
28
– – ﹤0.01% 5813
2017
Q1 		$333K Sell
28
-1
-3% -$14.1K ﹤0.01% 5377
2016
Q4 		$417K Hold
29
– – ﹤0.01% 5213
2016
Q3 		$609K Buy
29
+2
+7% +$38.8K ﹤0.01% 4853
2016
Q2 		$539K Buy
+27
New +$575K ﹤0.01% 4782
2016
Q1 		– Sell
-3
Closed -$48K – 7333
2015
Q4 		$48K Buy
+3
New +$48.9K ﹤0.01% 6566

Other funds holding TTNP

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's TTNP Position: Q4 2019 in Review

Goldman Sachs sold out of Titan Pharmaceuticals (TTNP) in Q4 2019, closing a stake of 19 shares — an estimated $3K sold.

Goldman Sachs first reported a position in TTNP in Q4 2015 and held it in 7 quarters. The position peaked at $609K in Q3 2016. 21 funds tracked by Wall St. Rank hold TTNP as of Q4 2019.

  • Goldman Sachs reported no remaining Titan Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Goldman Sachs sold 19 Titan Pharmaceuticals shares in Q4 2019, an estimated $3K.
  • Goldman Sachs first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 7 quarters.
  • Goldman Sachs's Titan Pharmaceuticals position peaked at $609K in Q3 2016.
  • 21 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2019.

Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.